54
Participants
Start Date
April 26, 2022
Primary Completion Date
May 22, 2023
Study Completion Date
May 22, 2023
FlecIH-103
flecainide acetate inhalation solution
DPC Hospital Egyesitett Szent Istvan es Szent Laszlo Korhaz, Budapest
Hospital General Universitario de Alicante, Alicante
Fundacion Hospital Son Liatzer, Palma de Mallorca
University of PACs, Pécs
Hospital Universitari Vall d'Hebron, Barcelona
Mount Sinal Hospital, New York
Weill Cornell Medical Center, New York
Hospital Santiago De Compostela, Santiago de Compostela
Thomas Jefferson University Hospital, Philadelphia
Reading Hospital, Reading
Nemocnice Slany, Slaný
Hospital Ramon y Cajal, Madrid
Fundacion Jimenez Diaz, Madrid
La Paz Univerisity Hospital, Madrid
Hospital Universitario Puera de Hierro, Madrid
Orlando Health Heart and Vascular Institute and Orlando Regional medical Center, Orlando
Tampa General Hospital; Center of Research Excellence, Tampa
The MetroHealth System, Cleveland
Cleveland Clinic Emergency Department, Cleveland
University of Cincinnati College of Medicine, Cincinnati
IU Health Ball Memorial Hospital, Muncie
Reid Physician Associates, Richmond
EDUMED s.r.o., Náchod
North Kansas City Hospital, Kansas City
University of Kansas Medical Center Research Institute, Kansas City
Memorial Care, Long Beach
UC Davis Medical Center, Davis
Bridgeport Hospital, Bridgeport
Saint Michaels Medical Center, Newark
The Valley Hospital, Inc, Ridgewood
Deventer Ziekenhuis, Deventer
Ziekenhuis Gelderse Vallei, Ede
Admiraal de Ruyter Ziekenhuis, Goes
Universitair Medisch Centrum Groningen (UMCG), Groningen
Spaarne Gasthuis, Haarlem
Medisch Centrum Leeuwarden, Leeuwarden
Diakonessenhuis, Utrecht
Maxima Medisch Centrum, Veldhoven
Mazowiecki Szpital Specjalistyczny w Ostrolece, Ostrołęka
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun
Lead Sponsor
InCarda Therapeutics, Inc.
INDUSTRY